Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy
Clinical Trials
Related News

Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)

Not Applicable
Conditions
Healthy Subjects
Interventions
Drug: Lorazepam
Drug: Placebo
First Posted Date
2011-01-10
Last Posted Date
2011-01-10
Lead Sponsor
Orasi Medical, Inc.
Target Recruit Count
16
Registration Number
NCT01272778
Locations
🇺🇸

Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

First Posted Date
2010-09-17
Last Posted Date
2017-11-17
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
11
Registration Number
NCT01204255
Locations
🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy

First Posted Date
2010-05-12
Last Posted Date
2010-05-31
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
372
Registration Number
NCT01121055
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test

First Posted Date
2009-09-09
Last Posted Date
2010-01-13
Lead Sponsor
Orasi Medical, Inc.
Target Recruit Count
15
Registration Number
NCT00972985
Locations
🇺🇸

Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

First Posted Date
2009-05-15
Last Posted Date
2009-09-23
Lead Sponsor
AstraZeneca
Target Recruit Count
100
Registration Number
NCT00902772
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

First Posted Date
2009-04-15
Last Posted Date
2021-08-17
Lead Sponsor
Columbia University
Target Recruit Count
3
Registration Number
NCT00881556
Locations
🇺🇸

The Children's Hospital, Aurora, Colorado, United States

🇺🇸

Morgan Stanley Children's Hospital of NYP, New York, New York, United States

🇺🇸

Children's Memorial Hospital, Chicago, Illinois, United States

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

Phase 2
Completed
Conditions
Anxiety Disorders
Interventions
Drug: AZD7325
Drug: Lorazepam
Drug: Placebo
First Posted Date
2008-12-15
Last Posted Date
2010-10-08
Lead Sponsor
AstraZeneca
Target Recruit Count
369
Registration Number
NCT00807937
Locations
🇺🇸

Research Site, Seattle, Washington, United States

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: AZD6280
Drug: Placebo
Drug: Lorazepam
First Posted Date
2008-09-11
Last Posted Date
2009-06-26
Lead Sponsor
AstraZeneca
Target Recruit Count
17
Registration Number
NCT00750802
Locations
🇳🇱

Research Site, Leiden, Netherlands

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

First Posted Date
2008-08-18
Last Posted Date
2012-05-28
Lead Sponsor
UCB Pharma
Target Recruit Count
20
Registration Number
NCT00736931

Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children

Phase 3
Completed
Conditions
Status Epilepticus
Seizures
Interventions
Drug: Lorazepam
First Posted Date
2008-08-15
Last Posted Date
2009-05-05
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Target Recruit Count
140
Registration Number
NCT00735527
Locations
🇮🇳

All India Institute of Medical Sciences, New Delhi, Delhi, India

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy